Speragen was founded by a mother of two children who are affected with a rare disease. Speragen knows first-hand the challenges of navigating a life with a rare disease:  from the daily challenges, the diagnostic odyssey, accepting the new reality post-diagnosis, finding a team of knowledgeable clinicians who can provide care, and finally to seeing the chasm between the current state treatment and when a therapy may be available.   Speragen, comes from the Latin word “spera” meaning “hope”, was formed to help solve these issues more rapidly by bridging the gulf from hope to the realization of a therapy.   

As a clinical stage biopharmaceutical corporation, Speragen has been able to rapidly advance therapeutic development.  Through a variety of strategies and collaboration with patients, families, academia and researchers, Speragen has a viable therapeutic candidate in late stage development and a growing pipeline.